Wroclaw, Poland

Centrum Badan Klinicznych

Hepatitis

Non-alcoholic Fatty Liver Disease

Hepatitis C

Hepatitis A

Asthma

Fatty Liver

UPB-101

Glecaprevir

IVA337

Aspartate

RPL554

Verekitug

Pibrentasvir

AbbVie

Inventiva Pharma

Upstream Bio

Verona Pharma

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate the incidence of asthma exacerbations, other pharmacodynamic (PD) parameters such as lung function and asthma control, and the safety and tolerability of verekitug (UPB-101) compared to placebo.

A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants with Severe Asthma (VALIANT)

Centrum Badan Klinicznych | Wroclaw, Poland

Site insights

Work at this site?

Active trials

A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants with Severe Asthma (VALIANT)

Trial sponsors